Clinical Trial Update: Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2 [Phase 4]

View source ↗

Summary

This document summarizes a Phase 4 clinical trial evaluating dapagliflozin, an SGLT-2 inhibitor, for reducing glycemic variability in adults with Type 2 diabete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• FARXIGA (dapagliflozin)

Snippet

Sponsor: Research Clinical Centre of the Russian Railways, JSC | Conditions: Diabetes Mellitus, Hypoglycemic Episodes | Phase 4 | Status: UNKNOWN